作者: John A. Hamilton , Andrew D. Cook , Paul P. Tak
DOI: 10.1038/NRD.2016.231
关键词: Novelty 、 Inflammation 、 Macrophage 、 Cancer 、 GM-CSF Receptor 、 Colony-stimulating factor 、 Bioinformatics 、 Drug discovery 、 Medicine 、 Clinical trial
摘要: Granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage (M-CSF; also known as CSF1), granulocyte (G-CSF) and interleukin-3 (IL-3) can each play a part in the host response to injury infection, there is burgeoning interest targeting these CSFs inflammatory autoimmune disorders, well cancer. For success clinical medicine, therapeutic will need be delineated from current strategies. The individual have unique biological roles, suggesting that they could used target specific conditions. This Review compares CSFs, with focus on how targeted, discusses relevant trial data summarizes potential applications of CSF. Importantly, we discuss novelty CSF biology attempt clarify some surrounding misconceptions issues affect decisions.